Innovent Biologics (09969) Surges Over 6% in Early Trading as BCL2 Inhibitor Mesutoclax Gains FDA Clinical Trial Approval for AML and MDS

Market Watcher

Jul 16

Innovent Biologics (09969) climbed more than 6% during early Hong Kong trading, with gains moderating to 5.24% at press time to HK$17.26. Trading volume reached HK$194 million. The biopharmaceutical firm announced that its self-developed novel BCL2 inhibitor mesutoclax (ICP-248), combined with azacitidine for treating myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), has received U.S. Food and Drug Administration (FDA) clearance for clinical studies. Public documentation indicates mesutoclax is a novel oral highly selective BCL2 inhibitor. BCL2 serves as a critical regulatory protein in cellular apoptosis pathways, with its abnormal expression linked to development of various hematological malignancies. By selectively inhibiting BCL2, mesutoclax reactivates programmed cell death mechanisms in tumor cells to exert anti-tumor effects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1164573183"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164573183\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164573183?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 00:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164573183","market":"us","top_or_hot":-1,"title":"Innovent Biologics (09969) Surges Over 6% in Early Trading as BCL2 Inhibitor Mesutoclax Gains FDA Clinical Trial Approval for AML and MDS","media":"Market Watcher","content":"<p>Innovent Biologics (09969) climbed more than 6% during early Hong Kong trading, with gains moderating to 5.24% at press time to HK$17.26. Trading volume reached HK$194 million. The biopharmaceutical firm announced that its self-developed novel BCL2 inhibitor mesutoclax (ICP-248), combined with azacitidine for treating myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), has received U.S. Food and Drug Administration (FDA) clearance for clinical studies. Public documentation indicates mesutoclax is a novel oral highly selective BCL2 inhibitor. BCL2 serves as a critical regulatory protein in cellular apoptosis pathways, with its abnormal expression linked to development of various hematological malignancies. By selectively inhibiting BCL2, mesutoclax reactivates programmed cell death mechanisms in tumor cells to exert anti-tumor effects.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics (09969) Surges Over 6% in Early Trading as BCL2 Inhibitor Mesutoclax Gains FDA Clinical Trial Approval for AML and MDS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics (09969) Surges Over 6% in Early Trading as BCL2 Inhibitor Mesutoclax Gains FDA Clinical Trial Approval for AML and MDS\n</h2>\n\n<h4 class=\"meta\">\n\n2025-07-16 00:45 北京时间&nbsp;&nbsp;&nbsp;<strong>Market Watcher</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innovent Biologics (09969) climbed more than 6% during early Hong Kong trading, with gains moderating to 5.24% at press time to HK$17.26. Trading volume reached HK$194 million. The biopharmaceutical ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1164573183","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164573183","pubTimestamp":1752597928,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Innovent Biologics (09969) climbed more than 6% during early Hong Kong trading, with gains moderating to 5.24% at press time to HK$17.26. Trading volume reached HK$194 million. The biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"laohu8.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK0239":"医药制造","09969":"诺诚健华","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"信达生物(09969)早盘大涨超6%，BCL2抑制剂Mesutoclax获FDA AML和MDS临床试验批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"09969":1},"content_text":"Innovent Biologics (09969) climbed more than 6% during early Hong Kong trading, with gains moderating to 5.24% at press time to HK$17.26. Trading volume reached HK$194 million. The biopharmaceutical firm announced that its self-developed novel BCL2 inhibitor mesutoclax (ICP-248), combined with azacitidine for treating myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), has received U.S. Food and Drug Administration (FDA) clearance for clinical studies. Public documentation indicates mesutoclax is a novel oral highly selective BCL2 inhibitor. BCL2 serves as a critical regulatory protein in cellular apoptosis pathways, with its abnormal expression linked to development of various hematological malignancies. By selectively inhibiting BCL2, mesutoclax reactivates programmed cell death mechanisms in tumor cells to exert anti-tumor effects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}